Rhabdoid Tumor Overview

Save information for later
Sign Up

Learn About Rhabdoid Tumor

What is the definition of Rhabdoid Tumor?
Rhabdoid tumor (RT) is an aggressive pediatric soft tissue sarcoma that arises in the kidney, the liver, the peripheral nerves and all miscellaneous soft-parts throughout the body. RT involving the central nervous system (CNS) is called atypical teratoid Rhabdoid tumor. RT usually occurs in infancy or childhood. In most cases, the first symptoms are linked to the compressive effects of a bulky tumor (such as respiratory distress, abdominal mass, peripheral nerve palsy). In about 90% of cases it is caused by a genetic change in the SMARCB1 gene, which is a tumor suppressor gene. In rare cases, it may be caused by a genetic change in the SMARCA4 gene. No standard care exists for RT, although there are many ongoing studies.
What are the alternative names for Rhabdoid Tumor?
  • Rhabdoid tumor
  • Atypical teratoid rhabdoid tumor
  • BRAIN TUMOR, POSTERIOR FOSSA, OF INFANCY, FAMILIAL
  • Malignant rhabdoid tumor
  • RHABDOID TUMOR PREDISPOSITION SYNDROME 1
  • Rhabdoid sarcoma
  • Rhabdoid tumor predisposition syndrome 2
Who are the top Rhabdoid Tumor Local Doctors?
Dr. Gary K. Schwartz
Oncology | Hematology
Dr. Gary K. Schwartz
Oncology | Hematology

University Hospitals Medical Group Inc

11100 Euclid Ave, 
Cleveland, OH 
 (67.0 mi)
216-844-1000
Experience:
46+ years
Languages Spoken:
English
Offers Telehealth

Gary Schwartz is an Oncologist and a Hematologist in Cleveland, Ohio. Dr. Schwartz has been practicing medicine for over 46 years and is rated as a Distinguished provider by MediFind in the treatment of Rhabdoid Tumor. His top areas of expertise are Rhabdoid Tumor Predisposition Syndrome, Rhabdoid Tumor, Rhabdomyosarcoma, and Ganglioneuroblastoma.

Dr. Ankit Mangla
Hematology Oncology | Hematology | Oncology
Dr. Ankit Mangla
Hematology Oncology | Hematology | Oncology

University Hospitals Medical Group Inc

11100 Euclid Ave, 
Cleveland, OH 
 (67.0 mi)
216-844-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ankit Mangla is a Hematologist Oncology specialist and a Hematologist in Cleveland, Ohio. Dr. Mangla and is rated as a Distinguished provider by MediFind in the treatment of Rhabdoid Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Melanoma, Angiosarcoma, and Undifferentiated Pleomorphic Sarcoma. Dr. Mangla is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Dr. David L. Bartlett
Surgical Oncology | General Surgery
Dr. David L. Bartlett
Surgical Oncology | General Surgery

Allegheny Clinic

4800 Friendship Ave, 
Pittsburgh, PA 
 (48.1 mi)
Languages Spoken:
English
See accepted insurances

David Bartlett is a Surgical Oncologist and a General Surgeon in Pittsburgh, Pennsylvania. Dr. Bartlett and is rated as an Experienced provider by MediFind in the treatment of Rhabdoid Tumor. His top areas of expertise are Pseudomyxoma Peritonei, Desmoplastic Small Round Cell Tumor, Colorectal Cancer, Pancreaticoduodenectomy, and Pancreatectomy.

View All Doctors
What are the latest Rhabdoid Tumor Clinical Trials?
Phase I/II Multicenter Study to Assess Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Phase I/II Multicenter Study to Assess Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Enrollment Status: Recruiting
Publish Date: January 07, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2

Summary: This is a Phase I/II study to assess the efficacy and safety of ribociclib in combination with topotecan and temozolomide (TOTEM) in pediatric patients with relapsed or refractory (r/r) neuroblastoma (NB), and other solid tumors, including medulloblastoma (MB), high-grade glioma (HGG), malignant rhabdoid tumors (MRT), and rhabdomyosarcoma (RMS).

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
A Phase 1/2 Study of Tiragolumab (NSC# 827799) and Atezolizumab (NSC# 783608) in Patients With Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
Enrollment Status: Recruiting
Publish Date: December 27, 2024
Intervention Type: Procedure, Other, Biological
Study Phase: Phase 1/Phase 2

Summary: This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory). SMARCB1 or SMARCA4 deficiency means that tumor cells are missing the SMARCB1 and SMARCA4 genes, seen with some aggressive cancers that are typically hard to treat. Immuno...

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center